This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bristol, ImClone Dispute Rights (Update)

Bristol-Myers Squibb (BMY - Get Report) stood by its bid for ImClone Systems (IMCL) this week, in the process raising a point of contention between the two companies that will be key to any potential buyer.

The pharmaceutical company and ImClone openly disagree on who owns the rights to a next-generation version of cancer drug Erbitux -- which will pose a significant threat to their shared product.

Greg Mayes, ImClone's vice president and interim general counsel said in the company's second-quarter conference call that ImClone believes it fully owns the IMC-11F8 molecule.

Bristol, which has marketing rights to Erbitux in the U.S., said in its most recent letter to ImClone's board that it also has U.S. rights to IMC-11F8 and other Erbitux-related products.

In a retort Thursday night, ImClone's chairman and activist investor Carl Icahn jabbed: "With regard to your assertion concerning rights to IMC-11F8 (which, if ultimately approved for sale, may have a significant competitive effect on ERBITUX), we disagree that Bristol's rights are clear and do not waive any rights that we may have with regard thereto."

IMC-11F8 is a fully humanized version of Erbitux, meaning it won't cause the severe allergic reactions that occur in some patients who take Erbitux, Senior Columnist Adam Feuerstein wrote on sister site ( subscription required) earlier this week. Theoretically, it should also be as effective, and thus could potentially overtake the Erbitux franchise.

Exactly what belongs to whom in the Bristol-ImClone partnership will be a key question of interest as ImClone's new mystery bidder conducts its due diligence over the next few weeks.

Earlier in the week, ImClone announced that it had received an offer from a large unnamed pharmaceutical company that trumps Bristol's $60 a share bid by $10 a share. Subsequently, ImClone's board officially deemed the Bristol proposal as inadequate.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
BMY $65.16 0.00%
IMCL $3.80 0.00%
YHOO $44.36 0.00%
AAPL $132.65 0.00%
FB $81.91 0.00%


DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs